Loading...
Derniers dépôts
-
Nicolas André, Marie Cécile Le Deley, Clémence Léguillette, Alicia Probst, Leen Willems, et al.. METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors. European Journal of Cancer, 2024, 198, pp.113525. ⟨10.1016/j.ejca.2024.113525⟩. ⟨hal-04653328⟩
-
Jeremie Naffrichoux, Pierre Poupin, William Pouillot, Claude Linassier, Nathalie Rioux-Leclercq, et al.. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort. European Journal of Cancer, 2024, 205, pp.114121. ⟨10.1016/j.ejca.2024.114121⟩. ⟨hal-04615732⟩
-
Charles de Marcellus, Arnault Tauziède-Espariat, Aurélie Cuinet, Claudia Pasqualini, Matthieu Robert, et al.. The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients. Journal of Neuro-Oncology, 2022, 157 (2), pp.355-364. ⟨10.1007/s11060-022-03970-4⟩. ⟨hal-03674693⟩
-
Antonio Di Meglio, Elise Martin, Tracy E Crane, Cecile Charles, Aude Barbier, et al.. A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design. Trials, 2022, 23 (1), pp.193. ⟨10.1186/s13063-022-06090-6⟩. ⟨inserm-04614681⟩
-
Susanne A Gatz, Anne C Harttrampf, Caroline Brard, Francisco Bautista, Nicolas André, et al.. Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial. Clinical Cancer Research, 2023, 30 (4), pp.741 - 753. ⟨10.1158/1078-0432.ccr-23-2959⟩. ⟨inserm-04590103⟩
-
Gilles Houvenaeghel, Alexandre De Nonneville, Monique Cohen, Jean-Marc Classe, Fabien Reyal, et al.. Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study. European Journal of Cancer, 2022, 176, pp.58-69. ⟨10.1016/j.ejca.2022.08.027⟩. ⟨hal-04084967⟩
-
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, et al.. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature Communications, 2024, 15 (1), pp.1985. ⟨10.1038/s41467-024-45974-w⟩. ⟨hal-04549309⟩
-
Lionel Perrier, Frederic Balusson, Magali Morelle, Joël Castelli, Juliette Thariat, et al.. Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial. Radiotherapy & Oncology, 2024, Radiotherapy and Oncology : Journal of the European Society For Therapeutic, 193, pp.110116. ⟨10.1016/j.radonc.2024.110116⟩. ⟨hal-04444231⟩
-
Roxane Machavoine, Sylvie Helfre, Valérie Bernier, Stéphanie Bolle, Julie Leseur, et al.. Locoregional Control and Survival in Children, Adolescents, and Young Adults With Localized Head and Neck Alveolar Rhabdomyosarcoma-The French Experience.. Frontiers in Pediatrics, 2022, Frontiers in Pediatrics, 9, pp.783754. ⟨10.3389/fped.2021.783754⟩. ⟨hal-04572907⟩
-
Guilhem Roubaud, M. Özgüroğlu, Nicolas Penel, N. Matsubara, N. Mehra, et al.. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.. European Journal of Cancer, 2022, European Journal of Cancer, 170, pp.73-84. ⟨10.1016/j.ejca.2022.04.016⟩. ⟨hal-04568938⟩
-
Anna Gueiderikh, Thomas Sarrade, Youlia M. Kirova, Brigitte de la Lande, Florent de Vathaire, et al.. Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors. Frontiers in Oncology, 2023, 13, ⟨10.3389/fonc.2023.1199043⟩. ⟨hal-04195134⟩
-
Justine Gantzer, Maud Toulmonde, François Séverac, Ali N. Chamseddine, Celine Charon-Barra, et al.. PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent. Cancer, 2024, ⟨10.1002/cncr.35277⟩. ⟨hal-04533834⟩
-
Renaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, et al.. Efficacité et tolérance du brigatinib chez des patients pris en charge pour un cancer bronchopulmonaire non à petite cellules avec translocation ALK en France. Étude BRIGALK.. Congrès de pneumologie de langue française, Jan 2019, Marseille, France. ⟨10.1016/j.rmr.2018.10.039⟩. ⟨hal-02633916⟩
-
Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, et al.. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). Lung Cancer, 2019, 136, pp.109-114. ⟨10.1016/j.lungcan.2019.08.010⟩. ⟨hal-04529929⟩